Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Do analysts prefer TARS or ROIV?

Tarsus Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 22.34%. Roivant Sciences has a consensus price target of $16.50, suggesting a potential upside of 39.77%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.25

Which has better valuation & earnings, TARS or ROIV?

Tarsus Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$182.95M	12.57	-$115.55M	-$2.33	-23.39
Roivant Sciences	$29.05M	276.25	-$171.98M	-$0.70	-16.86

Do insiders & institutionals hold more shares of TARS or ROIV?

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media favor TARS or ROIV?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 11 mentions for Roivant Sciences. Tarsus Pharmaceuticals' average media sentiment score of 0.98 beat Roivant Sciences' score of 0.49 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is TARS or ROIV more profitable?

Tarsus Pharmaceuticals has a net margin of -31.13% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-31.13%	-32.36%	-21.04%
Roivant Sciences	-2,111.79%	-15.90%	-14.95%

Which has more volatility & risk, TARS or ROIV?

Tarsus Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Roivant Sciences beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.